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Abstract
Background: In 2001 Health Canada responded to a series of Ontario court decisions by creating the Marihuana
Medical Access Division (MMAD) and the Marihuana Medical Access Regulations (MMAR). Although Health Canada
has conducted a small number of stakeholder consultations, the federal government has never polled federally
authorized cannabis patients. This study is an attempt to learn more about patient needs, challenges and
experiences with the MMAD.
Methods: Launched in the spring of 2007, Quality of Service Assessment of Health Canada’s Medical Cannabis Policy
and Program pairs a 50 question online survey addressing the personal experiences of patients in the federal
cannabis program with 25 semi-guided interviews. Data gathering for this study took place from April 2007 to Jan.
2008, eventually garnering survey responses from 100 federally-authorized users, which at the time represented
about 5% of the patients enrolled in Health Canada’s program. This paper presents the results of the survey
portion of the study.
Results: 8% of respondents report getting their cannabis from Health Canada, while 66% grow it for themselves.
>50% report that they frequent compassion clubs or dispensaries, which remain illegal and unregulated in Canada.
81% of patients would chose certified organic methods of cultivation; >90% state that not all strains are equally
effective at relieving symptoms, and 97% would prefer to obtain cannabis from a source where multiple strains are
available. Of the 48 patients polled that had tried the Health Canada cannabis supply, >75% rank it as either “1” or
“2” on a scale of 1-10 (with “1” being “very poor”, and 10 being “excellent”).
Discussion: 72% of respondents report they are either “somewhat” or “totally unsatisfied” with Canada’s medical
cannabis program. These survey results and relevant court decisions suggest that the MMAR are not meeting the
needs of most of the nation’s medical cannabis patient community. It is hoped this research will help inform policy
changes that will better address the needs of Canada’s critically and chronically ill medical cannabis patient
population, including the integration of community-based dispensaries into this novel healthcare delivery model.
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Background
According to the United Nations Office for Drug Con-
trol and Crime Prevention (2001) [1] cannabis is the
most popular illicit substance in the world. Despite the
high rate of recreational use and over 5000 years of
medical use, there has never been a substantiated case
of death resulting from cannabis overdose [2]. However,
the therapeutic use of cannabis remains highly contro-
versial, and only a few Western nations have introduced
policies or programs to allow legal access to medical
cannabis.
The Canadian government currently allows for limited
access to medical cannabis through the Marihuana
Medical Access Regulations (MMAR), which are admi-
nistered by Health Canada’s Marihuana Medical Access
Division (MMAD). These court-ordered regulations are
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cates, and have been found by courts to be unconstitu-
tional in a number of decisions for unnecessarily
limiting access to legal protection and a safe supply of
cannabis [3-6].
Initially established in response to patient needs and
ineffective or non-existent federal medical cannabis poli-
cies, community-based medical cannabis dispensaries
have become the main suppliers of medical cannabis in
both Canada and in many of the 14 U.S. states that have
legalized the medical use of cannabis [3,7]. In Canada,
community-based dispensaries, otherwise known as
“compassion clubs” currently supply over 30,000 criti-
cally or chronically ill Canadians with medical cannabis
[8]. Although Canadian dispensaries continue to operate
without legal sanction or protection, recent research
s u g g e s t st h a tt h i sp a t i e n t - c e n tered healthcare delivery
model builds social capital and provide patients with a
safe supply of cannabis within a supportive environment
that’s conducive to healing [3,7,5].
A Brief History of Cannabis as a Medicine
The medical use of cannabis can be traced back at least
5000 years. The oldest reports originate in China and
Egypt. It appears in a medical context in the Vedas,
India’s oldest religious text, and there are reports of its
use as a medicine from fragments of Assyrian texts dat-
ing back to 700 B.C. The famous Chinese doctor Hua
T’uo (approx. 100 A.D.) reportedly made use of a wine
and cannabis mixture as an anesthetic for surgical
operations [9].
There are numerous reports of the medicinal proper-
ties of cannabis from early in the nineteenth century,
the most famous of which is an 1839 report titled “on
the Preparations of the Indian Hemp, or Gunjah” by the
Irish doctor William B. O’Shaughnessy in which he
describes diverse applications for cannabis, including
rheumatism, rabies, cholera, tetanus, cramps and delir-
ium tremens [10]. A few years later Ernst Freiherr von
Bibra published the renown “Narcotics and the Human
Being”, devoting thirty pages to the therapeutic use of
cannabis preparations and hashish [11].
By the late 19
th Century, cannabis-based preparations
were manufactured and marketed by Burroughs-Well-
come & Co. In England; and Bristol-Meyers Squib,
Parke-Davis, and Eli Lilly in North America. The devel-
opment of vaccines to prevent the spread of common
infectious diseases, the increased use of opiates (with
the introduction of the hypodermic syringe), and the
discovery of aspirin at the end of the nineteenth and
early twentieth century resulted in cannabis-based medi-
cines losing their prevalence in the market place and
Western pharmacopoeia [2].
In Canada, the non-medical use of cannabis was out-
lawed as part of the Opium and Narcotics Drugs Act of
1923, largely based on a series of misleading articles
written by Emily Murphy for MacLean’sM a g a z i n ein
the early 1920’s which claimed cannabis turned people
into raving, blood-thirsty lunatics [12]. The US Pharma-
copoeia listed Cannabis until 1941 and stated that can-
nabis can be used for treating fatigue, coughing,
rheumatism, asthma, delirium tremens, migraine head-
aches, and the cramps and depressions associated with
menstruation [13,2].
Although modern research into therapeutic applica-
tions for cannabis has been seriously stymied by its pro-
hibition in most of the Western world, extensive
anecdotal reports and a growing body of laboratory and
clinical research suggest that it may have many medic-
inal uses, including hunger stimulation for wasting syn-
drome; anti-emetic and anti-nausea properties in AIDS
or cancer chemotherapy; anti-spasmodic properties for
MS, epilepsy and other neurological dysfunctions; redu-
cing intra-ocular eye pressure in glaucoma; and analge-
sic properties in a large number of chronic pain
conditions [14-16]. Recent research has found that can-
nabis can reduce the use of pharmaceutical drugs and
even be an effective treatment for addiction [17-20].
Medical Cannabis Access in Canada
Although the Canadian Addiction Survey suggests that
about 1 million Canadians use cannabis for medical pur-
poses [5], as of January 2010 the MMAD had only
authorized 4884 people in Canada to use cannabis leg-
ally [21]. Additionally, the federal supply of cannabis
produced by a company called Prairie Plant Systems
since 2000 remains highly problematic due to a lack of
strain selection, controversial production methods, and
patient concerns over the quality and safety [3-5].
Problems of safe access were noted by the Canadian
Senate Special Committee on Illegal Drugs in their final
report on cannabis from 2002, stating that:
while a process that authorizes the possession and
production of marijuana has been established in
Canada, this has not ensured that cannabis is suita-
bly available to those in need... we have come to the
conclusion that the MMAR have become a barrier
to access. Rather than providing a compassionate
framework, the regulations unduly restrict the avail-
ability of cannabis to those who may receive health
benefits from its use [22].
According to this report, one of the main reasons for
the small number of applicants to the program is reluc-
tance by physicians to act as gatekeepers to medicinal
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dosage, side effects, and alternate routes of administra-
tion to smoking, both the Canadian Medical Association
and the Canadian Medical Protection Agency (which
insures nearly 95% of Canada’s physicians) have warned
against the therapeutic use of cannabis, and have recom-
mended that doctors not participate in the federal pro-
gram. For example, a CMA press release dated July 9
th,
2003, declares:
The CMA has consistently raised concerns about the
lack of evidence-based decisions to support the
Medical Marijuana Access Regulations,” said Dr.
Dana Hanson, President of the CMA. “Our unease
over use of medical marijuana has been ignored in
this new policy. Physicians should not be the gate-
keeper for a substance for which we do not have
adequate scientific proof of safety or efficacy [23].
Such warnings have been a particular deterrent for
medical specialists, whose support was initially necessary
for all applicants to the program that were neither term-
inally ill nor likely to die in the next 12 months, such as
those suffering from MS, HIV/AIDS and hepatitis C
(terminal patients only required the support of a single
physician). In addition, specialists were simply not avail-
able in many smaller rural communities. When com-
pounded by the bureaucratic hurdle of filling out a 29-
page application that sometimes took in excess of 12
months for Health Canada to process, the challenges to
participation in this program ranged from onerous to
impossible for many potential applicants.
Health Canada officially amended the MMAD applica-
tion process in 2005 to remove the requirement of a
supportive specialist under most circumstances. How-
ever, the new “simplified” application form was now 33
pages long, and potential applicants continue to face
resistance from the medical community. The burden of
this difficult application process is apparent in compar-
ing the MMAD with the state-run Oregon Medical
Marijuana Program (OMMP), one of twelve state-admi-
nistered medical cannabis programs in the U.S.
Although both programs originated in 1999 and have
similar medical requirements for registration, Oregon’s
simple two page application process has led to the regis-
tration of 23,873 participants as of October 2009 (as
compared to just over 4000 in Canada during the same
period) - despite having a population one-tenth that of
Canada [24].
Community-Based Dispensaries
Community-based medical cannabis dispensaries, also
called “compassion clubs”, supply cannabis for therapeu-
tic use upon a valid recommendation or confirmation of
diagnosis from a licensed healthcare practitioner, and
reflect a patient-centered response to the suffering of
critically and chronically ill Canadians who might bene-
fit from the medical use of cannabis [3-5,7].
During the late 1980’s, as rates of HIV and AIDS
b e g a nt or i s ei nS a nF r a n c i s c o ,af e wu n d e r g r o u n dd i s -
pensaries began offering a safe source of cannabis to
those needing it for medical purposes were established
by compassionate people living with HIV/AIDS and
drug policy reform activists. With the successful passage
in 1996 of a state ballot initiative called “Proposition
215”, California became the first U.S. state to allow for
the legal medical use and distribution of cannabis.
Within a few weeks dozens of these “compassion clubs”
opened, and although they often had varied policies and
practices, their common goal was facilitating access to a
safe supply of cannabis for medical users [25]. Since
then, over 1000 community-based medical cannabis dis-
pensaries have opened up in California [26], and it is
estimated that they currently supply over 250,000 state
authorized patients [27]. Similar organizations have
emerged all over the world, and in Canada and the U.S.
these dispensaries remain the main source of cannabis-
based medicines for therapeutic use [3].
In Canada, a loose network of community-based dis-
pensaries provide over 30,000 critically and chronically
ill Canadians access to a safe supply of cannabis within
an environment conducive to healing [8]. Although
Canadian dispensaries continue to operate without legal
sanction or protection, communities, law enforcement,
and criminal courts across Canada have shown support
and tolerance for compassion clubs that self-regulate to
ensure their services are strictly for medical purposes
[3-5]
Quality of Service Assessment of Health Canada’s Medical
Cannabis Policy and Program
Although Health Canada hosted a stakeholder consulta-
tion in 2003 to address some of the early constitutional
and bureaucratic deficiencies of the MMAR, the opinion
of patients registered with the MMAD has never been
officially polled by the federal government in any sys-
tematic manner. This survey is an attempt to address
the dearth of information about actual patient experi-
ences with medical cannabis and Health Canada’s
program.
The study was funded by the McMaster Arts Research
Council, and ethics approval was granted by the
McMaster Research Ethics Board. Data gathering took
place from April 2007 to Jan. 2008, eventually garnering
survey responses from 100 federally-authorized users,
which at the time represented about 5% of the patients
enrolled in Health Canada’s program. The 50 item self-
administered survey combines multiple choice and
Lucas Harm Reduction Journal 2012, 9:2
http://www.harmreductionjournal.com/content/9/1/2
Page 3 of 11open-ended questions, and includes items informed by
validated questionnaires like the Short-Form Patient
Satisfaction Questionnaire (PSQ-18) and a 2005 ques-
tionnaire designed by Belle-Isle and the Canadian AIDS
Society to identify barriers to medical cannabis experi-
enced by Canadians affected by HIV/AIDS [5,6]. In
addition to basic socio-demographic data, survey ques-
tions generated by the researcher to address the history
of involvement and experiences with the federal pro-
gram, cannabis use patterns, and specific symptoms and
conditions that cannabis has relieved.
For privacy reasons Health Canada does not make a
list of federally authorized medical cannabis patients
available to the public, so recruiting for this study was
conducted through online and hard mail outreach to
medical cannabis patient internet discussion groups and
community-based dispensaries. In order to ensure that
survey participants were federally authorized patients,
respondents were asked to type in a specific word only
found on the authorized user ID card supplied by
Health Canada as a password to access the online ques-
tionnaire. Although the identity of survey respondents
will be kept completely anonymous, participants were
also asked to supply the registration number from their
Health Canada medical cannabis ID card to allow for
future verification/authentication if necessary.
Demographic Data
Study participants were > 78% male and 20.4% female,
and > 87% were 35 or older. Over 93% report that they
are Caucasian, with 3 participants identifying as First
Nations, 2 as Metis, and 1 as “black” (n = 97). In terms
of income 36.8% make less than $20,000, and > 61%
make less than $30,000, so this is a group that is well
below the medium income in Canada, which may be the
result of physical disabilities stemming from serious
and/or chronic medical conditions. Although a medical
expanse income tax claim can be filed for the cost of
cannabis purchased from the government, or produced
by individuals or their designated grower, there is cur-
rently no reimbursement of the actual costs of medical
cannabis. In light of these findings, it is unsurprising
that 46.3% of respondents state that they can “never”
afford enough cannabis to relieve their symptoms.
Despite the low-income levels, 77.8 had graduated from
high school, and 22.3% had a university degree (Table
1). According to Statistics Canada, this is slightly higher
than the Canadian average; the 2006 Census found that
just over 76% of Canadians had graduated from high
school, and that 18% had a university degree equivalent
to a Bachelor’s or higher [28].
Although there is no way to verify that this limited
sample is representative of participants in the MMAD, a
recent study by Reinarman et al assessing population
characteristics of 1746 California-based medical canna-
bis patients offers some useful comparisons. Reinarman
et al found that 72.9% of their sample was male, with
the researchers theorizing that the underrepresentation
of women may be related to the gender-distribution of
certain kinds of sports or workplace injuries, as well as
the “...double stigma women face in seeking MM (medi-
cal marijuana) - for using an illicit drug and for violating
gender-specific norms against illegal behavior in general”
[19].
Additionally, Reinarman et al found this population to
be of slightly higher education levels than the general
population, with 93.1% reporting at least high school
graduation, and 23.8% having a post-secondary degree,
which is also similar to this Canadian survey.
Patient Use Patterns and Preferences
While the overwhelming majority of participants
reported using cannabis recreationally prior to their
medical use, > 20% were cannabis-naïve prior to using it
medically (n = 89). The average years of medical use is
just over 10 years, which may be reflective of the older
p a t i e n tp r o f i l ea n da d d i t i o n a l l ys u g g e s t st h a tm a n y
patients have been using cannabis for far longer than
Health Canada’s federal program has been in existence.
When asked to check off all the major symptoms for
Table 1 Demographics of Federally Authorized, Medical
Cannabis Patients
Female 20.4%
Male 78.6%
Caucasian 93%
Metis 2%
Black 1%
Other 4%
18-24 2%
25-34 10.2%
35-44 23.5%
45-54 39.8%
55-64 23.4%
65-74 1%
Elementary School 5.1%
Secondary School 21.2%
Technical and Non-University Education 33.3%
University (Undergrad, BA) 18.2%
University (MA, PhD, post-doc) 5.1%
Less than $10 000 8.2%
$10 000-19 999 28.6%
$20 000-29 000 24.5%
$30 000-39 000 11.2%
$40 000-49 000 5.1%
$50 000-59 000 12.2%
$60 000 and over 10.2%
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symptoms: 84.1% cited pain relief, 78.4% cited relaxa-
tion, 61.4% cited appetite stimulation, 60.2% cited anxi-
ety reduction, 58% cited depression, 56.8% cited nausea
reduction/vomiting, 55.7% cited mood improvement,
43.2% cited desire to manage/gain weight, 42% cited
reduction in spasticity/tremors, and 23.9% cited side-
effects of other medications. Of interest is the high
number of individuals using cannabis for relaxation,
anxiety reduction, depression and mood improvement,
suggesting that patients with physical health conditions
may also be self-medicating for mental health issues
and/or general improvements in their quality of life (Fig-
ure 1).
In terms of personal use patterns, over 94% stated that
they use it every day, which is considerably higher than
the 67% reported by Reinarman et al from their Califor-
nia patient survey [19]. Over 88% smoke cannabis, and
71.6% report that they eat it. Over 52% have used vapor-
izers, 18.2% use tinctures and, unlike Europe, less than
4% mix it with tobacco. While the rate of smoking is
similar to the Reinarman et al sample, which found that
86.1% smoke cannabis [19], the comparatively higher
use oral ingestion/edibles (71.6% v. 24.4%) and vapori-
zers (52% v. 21.8%) in the Canadian sample may suggest
a greater level of concern and mitigation for potential
health impacts associated with smoking within the
Canadian patient population [29] (Figure 2). This health
awareness may also explain why 80.7% of respondents
prefer to use cannabis grown using certified organic cul-
tivation methods, whereas 19.3% either don’t care
(14.5%) or prefer non-organic cultivation (4.8%).
In terms of patient preferences and treatment efficacy,
90.9% report that not all strains are equally effective at
relieving their symptoms. As a result, 97.6% would pre-
fer to obtain cannabis from a source that offers a “large
selection of different strains” rather than 1 or 2 strains,
and over 90% would prefer to have access to raw canna-
bis as well as other methods of ingestion like baked
goods, tinctures, and hashish, compared with 9.8% who
would prefer a cannabis-only outlet. This creates a stark
contrast between access through Health Canada and
through community-based dispensaries. While Health
Canada offers a single strain of raw cannabis and no
alternatives to smoking, dispensaries make multiple
strains and methods of ingestion other than smoking
available to patients, including edibles, oils, tinctures,
salves, and even oromucosal sprays [3].
When asked about other cannabinoid-based pharma-
ceutical medicines like Marinol (dronabinol), Cesamet
Figure 1 Major Symptoms. Bar graph of self-reported major symptoms treated with cannabis by survey participants (n = 88).
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h a dt r i e dM a r i n o l ,a n d1 4 %h a dt r i e dS a t i v e x .4 3 %h a d
not tried any of the above, and 81.5% stated that didn’t
use any of these pharmaceuticals on a regular basis.
Patient Access to Medical Cannabis
When asked how they obtain cannabis, only 8.2% of
respondents report getting their cannabis from Health
Canada (although nearly half state that they have tried
the federal supply), while 80% grow it for themselves or
have it grown for them by a Designated Producer. Over
50% report that they frequent compassion clubs or dis-
pensaries, 38.8% report getting it from a friend, and >
22% get their medicine from street dealers (Figure 3).
When asked how they would rank the quality of the
cannabis from their regular source, 87.8% rank it as 7 or
above in a scale of 1-10, with 1 being “Very Poor”,a n d
10 being “Excellent”. By comparison, of the 41 patients
who have tried the federal cannabis supply, over 75%
rank it as either 1 or 2 on a scale of 1-10. While 3
r e s p o n d e n t sr a n k e di ta se i t h e ra6 ,7 ,o r8 ,n oo n e
ranked it any higher (Figure 4).
Since Health Canada’s cannabis supply went through
some modest improvements in regards to the size of the
grind, humidity level, and amount of THC in August
2004, respondents were asked when they tried this can-
nabis. Of the 39 who answered this question, 37 (or >
94%) used the federal supply between 2005-2007, and 2
used it before that. As such, it can be deducted that the
general dissatisfaction with the quality of the federal
cannabis supply is based on patient experiences with the
most recent “improved” version of this product.
W h e na s k e dw h a tt h e i rs i n g l ep r e f e r r e ds o u r c ef o r
medical cannabis would be, 65.1% stated that they
would like to grown their own, 24.1% cited dispensaries,
6% would like to get their medicine from a pharmacy,
4 . 8 %w o u l dl i k et og e ti tf r o maf r i e n d ,w h i l en e i t h e r
street dealers nor Health Canada were cited by a single
patient as their preferred source. This is highly relevant
since Health Canada’s proposed regulatory changes
include removing the right for individuals to produce
their own cannabis, despite this being the preferred
option cited by most study participants and the option
chosen by the majority of patients in the federal pro-
gram [30]. As of January 2010 (the latest statistics avail-
able on the Health Canada website) 3576 out of 4884 -
or over 73% - of federally authorized patients chose to
p r o d u c et h e i ro w nm e d i c i n eo rt oh a v eaD e s i g n a t e d
Producer do so for them [21]. If Health Canada intends
to make this program more patient-centered, removing
Figure 2 Methods of Ingestion. Bar graph of self-reported methods of cannabis ingestion reported by survey participants (n = 88).
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not appear to reflect current patient needs, and as such
this proposed significant amendment to the program
should be highly controversial, and will likely lead to
further court challenges by patients wishing to control
the cost and quality of their supply of medicine.
Patient Experiences With Health Canada Marihuana
Medical Access Division
Of study participants, nearly half (49.3%) became feder-
ally authorized patients in 2004 or later, while 50.7%
joined the program prior to 2004. When asked if they
had difficulty finding a physician to support their appli-
cation, exactly 50% said “yes”, and 50% answered “no”,
reflecting the diversity and unpredictability of medical
support available throughout Canada. In terms of pro-
cessing applications, 35.3% had theirs completed by
Health Canada within 2-4 months, and 29.4% state that
it took 60 days or less. However, 35.2% of participants
suggest that it took over 4 months, with 17.6% citing
that they waited over 12 months for their application to
be processed. This suggests that for those suffering from
serious or terminal conditions, processing times would
be a significant concern and may not be quick enough
to allow some patients to legally use cannabis in end-of-
life situations.
The following set of 6 questions put three statements
with positive connotations and 3 statements with negative
connotations to survey respondents, and are based on
standardized and validated Short-Form Patient Satisfaction
Questionnaire (PSQ-18) traditionally used to evaluate
health service delivery at hospitals, clinical and insurance
companies. In addressing the statement “I find the applica-
tion for a federal authorization simple and uncompli-
cated”, only 21.8% “agreed” or “strongly agreed”, while
71.2% “disagreed” or “strongly disagreed” (42.5%), suggest-
ing that for most patients the federal application process is
onerous and challenging. When asked to comment on the
statement “Employees at Health Canada’s MMAD act too
businesslike and impersonal towards me”,5 4 %“agreed” or
“strongly agreed”, while 28.7% “disagreed” or “strongly dis-
agreed”. In regards to the statement “I am dissatisfied with
the service I receive from Health Canada in regards to my
use of medical cannabis”, 68.9% “agree” or “strongly
agree”, while only 18.3% “disagree” or “strongly disagree”.
However, when asked if “Employees at Health Canada’s
MMAD treat me in a friendly and courteous manner”,
respondents were split, with 35.6% “agreeing” or “strongly
Figure 3 Access to Cannabis. Bar graph showing how survey participants access medical cannabis (n = 85).
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“strongly disagreeing”. When the statement “Ih a v ef u l l
confidence in the ability of the Health Canada employees
that administer this program” was put to patients, 76.8%
“disagreed” or “strongly disagreed”, with only 5.9% “agree-
ing” or “strongly agreeing” with the statement, and 17.4%
stating that they were “uncertain”. Finally, when asked “I
am able to get help from Health Canada in regards to my
medical use of cannabis whenever I need it”,8 . 2 %“agreed”
or “strongly agreed”, while 70.6% “disagreed” or “strongly
disagreed”, with 21.2% uncertain.
The final question of the survey asked participants to
rate their overall satisfaction with Health Canada’s med-
ical cannabis program, and 15.1% of patients state that
they are “completely” or “somewhat satisfied”, 12.8%
uncertain, and 72.1% either “somewhat” (20.9%) or
“totally unsatisfied” (51.2%) (Figure 5). This suggests a
very poor patient perception of the service quality at
Health Canada Marihuana Medical Access Division,
with many potential improvements in application pro-
cessing times, cannabis selection and quality and overall
responsiveness to patient queries and concerns.
In a federally-funded report titled “Our Rights, Our
Choice,’ which examined the human rights, ethical and
legal challenges faced by people living with HIV/AIDS
who choose to use medical cannabis, the Canadian
AIDS Society found that although between 14 to 37% of
people living with HIV/AIDS used cannabis to address
their condition, many had faced hurdles accessing the
federal program. The CAS report states that:
access to the federal program remains hindered by
barriers such as a lack of awareness of the program’s
existence, mistrust in the government, misinforma-
tion about the program and difficulty in finding a
physician to support their application. Thousands of
seriously ill Canadians must therefore choose
between breaking the law to use the therapy of their
choice, or going without, which in many cases com-
promises their well-being and quality of life [6].
The results of this federally authorized medical canna-
bis patient survey support the findings of the CAS study
and other research into the MMAR/MMAD [3-5].
Discussion
Creating policies and procedures for safe patient access
to medical cannabis has proven to be a challenge in
Canada and around the world. In the U.S., the 14 states
that allow for the legal use of cannabis continue to
Figure 4 Assessing Health Canada’s Cannabis Supply. Bar graph showing levels of satisfaction with the Health Canada medical cannabis
supply on a scale of 1-10, with 1 being “very poor” and 10 being “excellent” (n = 45).
Lucas Harm Reduction Journal 2012, 9:2
http://www.harmreductionjournal.com/content/9/1/2
Page 8 of 11struggle to protect patients, address access issues, and
mitigate community concerns, all of which is made all
the more complicated by ongoing resistance and active
legal threats by the federal government [7]. In Canada,
patients face multiple challenges to safe access: 1) resis-
tance from the medical community to act as gatekeepers
to the program; 2) an onerous application process; 3) a
very limited and much-criticized cannabis supply; 4)
limited income and a lack of national cost-coverage; and
5) ongoing social prejudice against the use of medical
cannabis [3-6]. Results from this survey suggest that
reducing bureaucratic obstacles while increasing patient
options for access would result in greater levels of
patient participation and overall satisfaction with the
federal program.
While there is a remarkable diversity in the demo-
graphics and medical conditions of cannabis patients,
some common themes emerge from this research. It is
clear that patients’ would like to have a choice of many
different strains and forms of ingestion in order to more
safely and effectively address their many different symp-
toms and conditions. Since cost continues to be a signif-
icant obstacle for patients with low or fixed income,
provincial or federal cost-reduction or coverage policies
should be implemented [5,6]. The high bureaucratic
burden on both patients and physicians is reducing par-
ticipation in the program, so allowing healthcare provi-
ders to treat cannabis like any other medicine would
likely improve uptake and might also alleviate some of
the social stigma associated with the therapeutic use of
cannabis. Since this study and Health Canada’s own sta-
tistics [21] show that the majority of participants in the
Canadian federal program chose to produce their own
medicine, policies and procedures should be put in
place that maintain the option of personal production
while also ensuring that both patients and communities
are protected from the dangers of poorly-cultivated can-
nabis. This could range from basic information from
Health Canada on safe production practices to electrical
inspections at the municipal level. Additionally, with
over half of respondents currently accessing cannabis
through dispensaries and growing evidence that these
organizations build social capital and provide an envir-
onment that is conducive to health and healing [3-7],
the federal government should work with dispensaries
to develop regulations that would incorporate this com-
munity-based model of access into Canada’s medical
cannabis program.
Figure 5 Overall Satisfaction with Health Canada Medical Cannabis Program. Bar graph of overall level of satisfaction with Health Canada’s
medical cannabis program reported by survey participants (n = 86).
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Page 9 of 11Finally, many of the challenges faced by the MMAD
could have been addressed or avoided through a more
robust and active strategy for patient engagement and
involvement. Although there are many stakeholders
directly or indirectly affected by the federal medical can-
nabis program - municipalities, police, physicians, etc. -
the key stakeholders are the Canada’s critically or
chronically ill who could or do benefit from the use of
cannabis. Unfortunately, the short history of the
MMAR/MMAD shows that the needs and concerns of
patients has all too often been ignored or overshadowed
by other interests and concerns [3-6]. The future suc-
cess of this cutting-edge program will depend largely on
the willingness of the federal government to create a
truly patient-centered approach to medical cannabis
access, including active and ongoing engagement with
end-users, support for research into the potential harms
and benefits of medical cannabis, and increased options
for patients, potentially through the regulation of com-
munity-based dispensaries.
There are a few limitations to this study. Although
participants represented about 5% of the patient popula-
tion in the program at the time of the survey there is no
way to know how representational this cohort is to the
rest of the participants in the MMAD since Health
Canada has never released any demographic information
about federally authorized users. Additionally, since
recruiting was largely done online and through medical
cannabis patient lists and groups, it is possible that this
more active population has a higher level of dissatisfac-
tion with the federal program. However, the general
demographics of participants in this study is similar to
those identified by Reinarman in a recent U.S.-based
study [19], and many of the patient needs and chal-
lenges that came to light in this survey support previous
research on Canada’s medical cannabis population and
associated federal program [3-6]. It is hoped that this
survey, which represents the first polling ever conducted
solely on federally authorized patients in Canada, will
assist policy-makers here and abroad develop more
patient-centered strategies for safe access to medical
cannabis.
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